6:12 PM
 | 
May 09, 2013
 |  BC Extra  |  Company News

Salix appealing Relistor complete response

Salix Pharmaceuticals Inc. (NASDAQ:SLXP) disclosed in its post-market 1Q13 earnings that it submitted an appeal to FDA for a July 2012 complete response letter for an sNDA for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with non-cancer pain. Salix said...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >